Month: March 2022

Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipeline Clinical development commencing for two programs that incorporate Lyell’s novel reprogramming technologiesSOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported fourth quarter and full year 2021 financial results and provided business highlights. “With the recent FDA clearance of two INDs that incorporate our novel genetic and epigenetic reprogramming technologies, we are now a clinical stage-company advancing a pipeline of novel cell therapies for patients with solid tumors,” said Liz Homans, CEO of Lyell Immunopharma....

CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today reported financial results for the full year ended December 31, 2021 and provided a business update. “2021 was a transformational year for Pardes, culminating in the completion of our business combination and successful financing, which positioned us well to continue working urgently to develop PBI-0451 as a potential stand-alone oral antiviral drug candidate for the treatment and prevention of COVID-19. We have seen oral antiviral treatments begin to emerge, and while they are a great starting...

SUNNYVALE, Calif., March 29, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2021 and filed its annual report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission. The Company will also hold an update conference call at 4:30 PM ET in which it will discuss business highlights. Following management’s formal remarks, there will be a question and answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10164538/f1ee9a93ce.  Please note that registered participants will receive their dial-in number upon registration.  For those who have not registered, to listen...

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives. Business UpdateTricida continued to execute on the conduct of the VALOR-CKD renal outcomes clinical trial. Enrollment of patients in the VALOR-CKD trial was completed at the end of 2021 with 1,480 subjects randomized. As of March 28, 2022, randomized subjects had an average treatment duration of approximately 24 months, and the trial had accrued 217 subjects with positively adjudicated primary endpoint events, defined as renal death, end-stage renal disease (ESRD), or greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR).  Upcoming MilestoneTricida...

– Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis – – Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg – – Strengthened Board with the appointments of Lyn Baranowski and Lisa Rometty – – Conference call and webcast today at 4:30 p.m. ET – SAN JOSE, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “The year 2021 and the subsequent months that have passed have been a productive period for Rani. We refined and progressed our development...

Ended 2021 with $217 million in unrestricted cash and cash equivalents Completed assembly and began initial testing of the initial Guardian® XT™ “Beta” unit Completed scheduled move into new headquarters in Salt Lake City SALT LAKE CITY, March 29, 2022 (GLOBE NEWSWIRE) — Sarcos Technology and Robotics Corporation (“Sarcos”) (NASDAQ: STRC and STRCW), a leader in the development of highly dexterous robotic systems that augment humans to enhance productivity and safety, today announced financial results for the quarter and full-year ended December 31, 2021. Recent highlights include:Announced the planned acquisition of RE2 Robotics, an award-winning developer of intelligent mobile manipulation systems Started testing of the Guardian® XO® Beta unit functionality Appointed Kiva Allgood as new President and Chief Executive Officer Completed...

Record fourth quarter revenue of $19.0 million, representing growth of 106% compared to the prior year period; organic revenue growth was 77.6%, excluding contribution from the 2WR+ acquisition. Full year 2021 revenue was $62.1 million, representing growth of 140%. Fourth quarter net loss of ($0.6) million; full year 2021 net loss was ($0.9) million Fourth quarter Adjusted EBITDA1 of $0.5 million; full year 2021 Adjusted EBITDA of $2.7 million, representing an Adjusted EBITDA margin of 4.3% of revenue Project backlog of contractually committed equipment and service orders with deposits received was $30.2 million as of December 31, 2021 Strong balance sheet with $34.6 million in cash and no debt Provides 2022 revenue guidance of greater than $110 million and Adjusted EBITDA guidance of greater than $5.0 million, including partial year...

Call scheduled for today, March 29, at 4:30 pm ET TUCSON, Ariz., March 29, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its financial results for the year ended December 31, 2021. Recent Business HighlightsHTG Transcriptome Panel (“HTP”) revenue continued to increase in the fourth quarter of 2021, ending the year as the top selling assay at approximately 16% of total revenue, just 5 months after commercial sales availability.Announced the expansion of its therapeutics team with the addition of several highly experienced professionals, led by Stephen Barat, Ph.D., a drug development veteran who most recently served with the Janssen Pharmaceutical Companies of Johnson...

FREDERICK, Md., March 29, 2022 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ:TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the fourth quarter and year ended December 31, 2021. TOMI Chief Executive Officer, Dr. Halden Shane, stated, “Over the last two years, our Company has made dramatic progress growing our customer list, diversifying our product line through internal innovation, enhancing brand recognition, and positioning TOMI as a major player in the disinfection markets. As expected, 2021 revenue decreased from the previous year because 2020 saw a surge in demand for disinfection products at the onset of the COVID-19 pandemic....

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) — Stronghold Digital Mining, Inc. (Nasdaq: SDIG) (“Stronghold,” or the “Company”) today reported financial results for its fourth quarter and full year ended December 31, 2021, and provided an operational update. Fourth Quarter and Year-End 2021 and Recent Operational and Financial HighlightsRemoved approximately 264,561 tons of coal refuse and returned approximately 141,876 tons of beneficial use ash to waste coal sites during the fourth quarter, facilitating the remediation of these sites. As of December 31, 2021, we had received a total of 14,700 miners with total hash rate capacity of approximately 1.3 exahash per second (“EH/s”). As of March 24, 2022, we had received approximately 25,200 miners with total hash rate capacity of approximately 2.3 EH/s. As of March 24, 2022, we have...